Deep-pocketed investors have adopted a bearish approach towards Intellia Therapeutics NTLA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NTLA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Intellia Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 53% bearish. Among these notable options, 6 are puts, totaling $497,000, and 9 are calls, amounting to $788,361.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $30.0 for Intellia Therapeutics, spanning the last three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Intellia Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Intellia Therapeutics's whale activity within a strike price range from $25.0 to $30.0 in the last 30 days.
Intellia Therapeutics Option Activity Analysis: Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA | CALL | SWEEP | BULLISH | 01/17/25 | $9.0 | $8.4 | $8.96 | $25.00 | $154.5K | 259 | 1.0K |
| NTLA | CALL | SWEEP | BULLISH | 01/17/25 | $8.6 | $8.2 | $8.49 | $25.00 | $140.0K | 259 | 165 |
| NTLA | PUT | SWEEP | BULLISH | 01/17/25 | $5.1 | $5.0 | $5.0 | $25.00 | $136.5K | 545 | 273 |
| NTLA | CALL | SWEEP | BEARISH | 01/17/25 | $8.7 | $8.6 | $8.6 | $25.00 | $103.2K | 259 | 521 |
| NTLA | PUT | SWEEP | BEARISH | 01/17/25 | $5.0 | $4.9 | $5.0 | $25.00 | $96.0K | 545 | 749 |
About Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Current Position of Intellia Therapeutics
- With a volume of 534,743, the price of NTLA is up 3.26% at $27.9.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 35 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intellia Therapeutics with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
